China Addiction Therapeutics Market Analysis

China Addiction Therapeutics Market Executive Summary

China addiction therapeutics market was valued at $812 Mn in 2022 and is estimated to reach $1548 Mn in 2030, exhibiting a CAGR of 8.4% during the forecast period.

Addiction therapy is a broad field that includes a range of interventions and treatments meant to assist people in recovering from drug use disorders. This covers a variety of techniques, including medication-assisted treatments (MAT), which use drugs to control cravings and withdrawal symptoms, and behavioural therapies, which deal with the psychological components of addiction. Furthermore, social support systems and local resources are essential for long-term rehabilitation. Two commonly prescribed medications used in the ongoing treatment of opioid use disorder addiction are methadone and buprenorphine. Other medications that are approved for the treatment of substance use disorders include naltrexone, acamprosate, and disulfiram, however, these may not be initiated until after detox.

Drug addiction is a major issue in China even with strict laws and punishments for using illegal drugs. Methamphetamine, ketamine, heroin, and cannabis are among the drugs that are most frequently abused in the nation. In addition to conducting preventative programs to increase public awareness, the government targets drug production and distribution with strict law enforcement measures and offers treatment and rehabilitation facilities. By the end of 2022, there were a total of 1.124 Mn drug users across the nation. Notably, within the same timeframe, 71,000 new users were identified. 416,000 uses heroin, 588,000 consumes methamphetamine, and 32,000 use ketamine. The use of narcotic medicines, psychotropic drugs (such as tramadol and diclazepam), and New Psychoactive Substances (NPS) (such as fluoroketamine and synthetic cannabinoids) increased significantly during the year.

To address alcoholism, 3SBio Inc. presented positive preclinical results for its GPCR (G protein-coupled receptor) antagonist, demonstrating their commitment to developing novel targeted addiction treatments.

Zhejiang NHU Company has shown its dedication to bettering overdose management by concentrating on researching naloxone nasal sprays and other creative formulations to increase naloxone's accessibility and utility for opioid overdose reversal.

Market Dynamics

Market Growth Drivers

• Government Initiatives: The market for addiction therapies may expand as a result of the government's efforts to combat drug abuse and addiction by supporting treatment, rehabilitation programs, and public awareness campaigns. The need for pharmaceutical products connected to substance abuse is increased by government support and investments.
• Changing Societal Attitudes: As mental health and addiction become more widely recognized, more people are seeking treatment as a result of these developments. Decreased stigma around substance abuse problems encourages more people to seek treatment, which increases the market for drugs used to treat addiction.
• Healthcare Infrastructure Development: By creating treatment centres and rehabilitation facilities and by continuously building out healthcare infrastructure, more people will have access to addiction treatment medications and related services, which will promote market expansion.

Market Restraints

• Stringent Regulations and Approval Process: Getting approval for addiction treatment medications from the China National Medical Products Administration (NMPA) can be extremely difficult and time-consuming. Strict assessments of quality, safety, and efficacy combined with the difficulty of complying with regulatory standards can cause new drugs to be released into the market more slowly.
• Stigma and Cultural Attitudes: The stigma associated with mental health disorders and addiction in society may deter people from getting treatment. Cultural beliefs that view addiction as a personal shortcoming instead of a disease may make it more difficult for those who are affected to seek out therapeutic interventions.
• Affordability and Insurance Coverage: Some people may have concerns about the cost of addiction therapy medications and services. High out-of-pocket costs and a lack of insurance coverage may make it difficult to obtain essential prescription drugs and all-encompassing treatment plans. High out-of-pocket expenses for addiction treatment restraints the market from growing.

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA) of China is in charge of the stringent registration and approval procedures for pharmaceutical products, which includes pharmaceuticals used as addiction therapies. Manufacturers are required to get NMPA clearance before marketing and distributing these drugs. This means conducting rigorous assessments of safety, effectiveness, quality, and production standards. To avoid abuse and diversion, China also uses a rigid system of drug classification, closely regulating compounds that are narcotic and psychotropic. To guarantee efficacy before market release and conformity to ethical guidelines, the NMPA also oversees clinical studies for novel pharmaceuticals. In addition, pharmaceutical firms bargain with government agencies over price and reimbursement to get access to the market, and strict adherence to Good Manufacturing Practice (GMP) guidelines guarantees production safety. Public awareness campaigns, law enforcement actions, and treatment service support are some of the ways that the Chinese government combats drug misuse.

Competitive Landscape

Key Players

• Yabao Pharmaceutical Group
• Tasly Pharmaceutical Group
• China Meheco Corporation
• Tonghua Dongbao Pharmaceutical
• Harbin Pharm. Group Sanjing
• Zhejiang NHU,
• Shanghai Pharmaceuticals Holding
• Jiangsu Hengrui Medicine
• Fosun Pharmaceutical
• 3SBio Inc.